Lab tests of a drug called abexinostat on tough glioblastoma cells
Original title: Abexinostat attenuates temozolomide-resistant glioma stem cells.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done in lab cells and in mice.
The short version
This is early lab and mouse work on a drug aimed at tumor cells that survive chemo.
What was studied. Researchers tested a drug called abexinostat on glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells grown from patients. They also tested it in mice that carried human tumors, both alone and with the chemo drug temozolomide.
What they found. Abexinostat lowered proteins that tumor cells use to repair their DNA. It also caused the cells to die. It cut markers of glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary stem cells, the cells linked to tumors coming back. In mice, it slowed tumor growth and lowered those same stem cell markers.
What this means, and what it doesn't
What it could mean: A doctor cannot offer this drug for a brain tumor today. The results give researchers a reason to keep studying it. Any use for patients would be years away, if it happens at all.
What it doesn't mean: This does not mean a new treatment is ready. The work was done in cells in a dish and in mice. It was not tested in people with brain tumors. It is not a cure, and it is not a promise that anyone will live longer.
Source: PubMed, August 19, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.